Skye Bioscience, Inc.

NasdaqGM:SKYE Stock Report

Market Cap: US$125.0m

Skye Bioscience Management

Management criteria checks 1/4

Skye Bioscience's CEO is Punit Dhillon, appointed in Aug 2020, has a tenure of 4.25 years. total yearly compensation is $1.81M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 1.12% of the company’s shares, worth $1.40M. The average tenure of the management team and the board of directors is 2.5 years and 0.7 years respectively.

Key information

Punit Dhillon

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage24.9%
CEO tenure4.3yrs
CEO ownership1.1%
Management average tenure2.5yrs
Board average tenureless than a year

Recent management updates

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11
Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

CEO Compensation Analysis

How has Punit Dhillon's remuneration changed compared to Skye Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$450k

-US$38m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$668kUS$433k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$9m

Dec 31 2021US$900kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$615kUS$160k

-US$7m

Sep 30 2020n/an/a

-US$207k

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$13m

Dec 31 2019US$65kn/a

US$1m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$82kn/a

-US$19m

Compensation vs Market: Punit's total compensation ($USD1.81M) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Punit's compensation has increased whilst the company is unprofitable.


CEO

Punit Dhillon (44 yo)

4.3yrs

Tenure

US$1,807,338

Compensation

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...


Leadership Team

NamePositionTenureCompensationOwnership
Punit Dhillon
President4.3yrsUS$1.81m1.12%
$ 1.4m
Kaitlyn Arsenault
Chief Financial Officer3.1yrsUS$1.27m0.55%
$ 685.3k
Christopher Twitty
Chief Scientific Officer1.9yrsno datano data
Tu Diep
Chief Development Officerno datano data0.27%
$ 338.9k
Puneet Arora
Chief Medical Officerless than a yearno datano data

2.5yrs

Average Tenure

43.5yo

Average Age

Experienced Management: SKYE's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Punit Dhillon
President6.8yrsUS$1.81m1.12%
$ 1.4m
Paul Grayson
Independent Chairman of the Board1.3yrsUS$1.25m0.86%
$ 1.1m
Andrew Schwab
Director1.3yrsUS$74.08k0%
$ 0
Louis Aronne
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Annalisa Lisa Jenkins
Independent Directorless than a yearno data0%
$ 0
Karen Smith
Directorless than a yearno data0%
$ 0
Deborah Charych
Independent Director1.8yrsUS$102.28k0%
$ 0
Rekha Kumar
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Lee Kaplan
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Beverly Tchang
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Marcus Goncalves
Member of Clinical & Scientific Advisory Boardless than a yearno datano data

0.7yrs

Average Tenure

59yo

Average Age

Experienced Board: SKYE's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.